Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19614020 | 0.92 | MAPK1 (0.70) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL25767297 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL22021801 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19509484 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19871891 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL23031873 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL26249989 | 0.89 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL16393106 | 0.88 | MAPK1 (0.73) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL16392632 | 0.88 | MAPK1 (0.73) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL10333760 | 0.87 | MAPK1 (0.75) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687024-B1 | CARBOHYDRATE ANTIGEN-NANOPARTICLE CONJUGATES AND USES THEREOF AS ANTIMETASTATIC AGENTS IN TREATING CANCER | US GOV HEALTH & HUMAN SERV (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20070275007-A1 | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN S (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1687024-A2 | CARBOHYDRATE ANTIGEN-NANOPARTICLE CONJUGATES AND USES THEREOF AS ANTIMETASTATIC AGENTS IN TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005046722-A2 | CARBOHYDRATE ANTIGEN-NANOPARTICLE CONJUGATES AND USES THEREOF AS ANTIMETASTATIC AGENTS IN TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275007-A1 | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer | CA14, CA13, CA12 | MAPK1 2554/4885LGALS8 36/4885LGALS3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.